- Home
- IMAB vs CRBP Comparison
IMAB vs CRBP Comparison
Compare IMAB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- CRBP
- Stock Information
- Founded
- IMAB 2014
- CRBP 2009
- Country
- IMAB United States
- CRBP United States
- Employees
- IMAB N/A
- CRBP N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- CRBP Health Care
- Exchange
- IMAB Nasdaq
- CRBP Nasdaq
- Market Cap
- IMAB 73.9M
- CRBP 73.4M
- IPO Year
- IMAB 2020
- CRBP N/A
- Fundamental
- Price
- IMAB $1.31
- CRBP $7.42
- Analyst Decision
- IMAB Strong Buy
- CRBP Strong Buy
- Analyst Count
- IMAB 2
- CRBP 10
- Target Price
- IMAB $5.50
- CRBP $53.56
- AVG Volume (30 Days)
- IMAB 238.6K
- CRBP 114.7K
- Earning Date
- IMAB 05-15-2025
- CRBP 05-06-2025
- Dividend Yield
- IMAB N/A
- CRBP N/A
- EPS Growth
- IMAB N/A
- CRBP N/A
- EPS
- IMAB N/A
- CRBP N/A
- Revenue
- IMAB N/A
- CRBP N/A
- Revenue This Year
- IMAB N/A
- CRBP N/A
- Revenue Next Year
- IMAB N/A
- CRBP $150.00
- P/E Ratio
- IMAB N/A
- CRBP N/A
- Revenue Growth
- IMAB N/A
- CRBP N/A
- 52 Week Low
- IMAB $0.60
- CRBP $4.64
- 52 Week High
- IMAB $2.00
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- IMAB 76.59
- CRBP 53.76
- Support Level
- IMAB $0.90
- CRBP $7.05
- Resistance Level
- IMAB $1.47
- CRBP $7.62
- Average True Range (ATR)
- IMAB 0.10
- CRBP 0.50
- MACD
- IMAB 0.04
- CRBP -0.01
- Stochastic Oscillator
- IMAB 74.07
- CRBP 55.97
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.